LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Publisher: Wiley
Languages: English
Types: Article
Subjects: RS, RM
Identifiers:doi:10.1002/jps.24681
In this study, Taguchi design was used to determine optimal parameters for the preparation of bovine serum albumin (BSA)-loaded nanoparticles (NPs) using a biodegradable polymer poly(glycerol adipate-co-ω-pentadecalactone) (PGA-co-PDL). NPs were prepared, using BSA as a model protein, by the double emulsion evaporation process followed by spray-drying from leucine to form nanocomposite microparticles (NCMPs). The effect of various parameters on NP size and BSA loading were investigated and dendritic cell (DC) uptake and toxicity. NCMPs were examined for their morphology, yield, aerosolisation, in vitro release behaviour and BSA structure. NP size was mainly affected by the polymer mass used and a small particle size ≤500 nm was achieved. High BSA (43.67 ± 2.3 μg/mg) loading was influenced by BSA concentration. The spray-drying process produced NCMPs (50% yield) with a porous corrugated surface, aerodynamic diameter 1.46 ± 141 μm, fine particle dose 45.0 ± 4.7 μg and fine particle fraction 78.57 ± 0.1%, and a cumulative BSA release of 38.77 ± 3.0% after 48 h. The primary and secondary structures were maintained as shown by sodium dodecyl sulphate poly (acrylamide) gel electrophoresis and circular dichroism. Effective uptake of NPs was seen in DCs with >85% cell viability at 5 mg/mL concentration after 4 h. These results indicate the optimal process parameters for the preparation of protein-loaded PGA-co-PDL NCMPs suitable for inhalation. © 2015 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Reichert JM. 2003. Trends in development and approval times for new therapeutics in the United States. Nat Rev Drug Discov 2(9):695- 702.
    • 2. Kunda NK, Somavarapu S, Gordon SB, Hutcheon GA, Saleem IY. 2013. Nanocarriers targeting dendritic cells for pulmonary vaccine delivery. Pharm Res 30(2):325-341.
    • 3. Sou T, Meeusen EN, de Veer M, Morton DA, Kaminskas LM, McIntosh MP. 2011. New developments in dry powder pulmonary vaccine delivery. Trends Biotechnol 29(4):191-198.
    • 4. Pulliam B, Sung JC, Edwards DA. 2007. Design of nanoparticlebased dry powder pulmonary vaccines. Expert Opin Drug Deliv 4(6):651-663.
    • 5. Rytting E, Nguyen J, Wang X, Kissel T. 2008. Biodegradable polymeric nanocarriers for pulmonary drug delivery. Expert Opin Drug Deliv 5(6):629-639.
    • 6. Foged C, Brodin B, Frokjaer S, Sundblad A. 2005. Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. Int J Pharm 298(2):315-322.
    • 7. Kunda NK, Alfagih IM, Dennison SR, Tawfeek HM, Somavarapu S, Hutcheon GA, Saleem IY. 2015. Bovine serum albumin adsorbed PGAco­PDL nanocarriers for vaccine delivery via dry powder inhalation. Pharm Res 32(4):1341-1353.
    • 8. Kallinteri P, Higgins S, Hutcheon GA, St Pourcain CB, Garnett MC. 2005. Novel functionalized biodegradable polymers for nanoparticle drug delivery systems. Biomacromolecules 6(4):1885-1894.
    • 9. Thompson CJ, Hansford D, Higgins S, Rostron C, Hutcheon GA, Munday DL. 2007. Evaluation of ibuprofen­loaded microspheres prepared from novel copolyesters. Int J Pharm 329(1-2):53-61.
    • 10. Tawfeek H, Khidr S, Samy E, Ahmed S, Murphy M, Mohammed A, Shabir A, Hutcheon G, Saleem I. 2011. Poly(glycerol adipate­co­omegapentadecalactone) spray­dried microparticles as sustained release carriers for pulmonary delivery. Pharm Res 28(9):2086-2097.
    • 11. Tawfeek HM, Evans AR, Iftikhar A, Mohammed AR, Shabir A, Somavarapu S, Hutcheon GA, Saleem IY. 2013. Dry powder inhalation of macromolecules using novel PEG­co­polyester microparticle carriers. Int J Pharm 441(1-2):611-619.
    • 12. Lu D, Hickey AJ. 2007. Pulmonary vaccine delivery. Expert Rev Vaccines 6(2):213-226.
    • 13. Stocke NA, Meenach SA, Arnold SM, Mansour HM, Hilt JZ. 2015. Formulation and characterization of inhalable magnetic nanocomposite microparticles (MnMs) for targeted pulmonary delivery via spray drying. Int J Pharm 479(2):320-328.
    • 14. Ungaro F, d'Angelo I, Miro A, La Rotonda MI, Quaglia F. 2012. Engineered PLGA nano­ and micro­carriers for pulmonary delivery: Challenges and promises. J Pharm Pharmacol 64(9):1217-1235.
    • 15. Sinsuebpol C, Chatchawalsaisin J, Kulvanich P. 2013. Preparation and in vivo absorption evaluation of spray dried powders containing salmon calcitonin loaded chitosan nanoparticles for pulmonary delivery. Drug Des Devel Ther 7:861-873.
    • 16. McBride AA, Price DN, Lamoureux LR, Elmaoued AA, Vargas JM, Adolphi NL, Muttil P. 2013. Preparation and characterization of novel magnetic nano­in­microparticles for site­specific pulmonary drug delivery. Mol Pharm 10(10):3574-3581.
    • 17. Amaro MI, Tajber L, Corrigan OI, Healy AM. 2011. Optimisation of spray drying process conditions for sugar nanoporous microparticles (NPMPs) intended for inhalation. Int J Pharm 421(1):99-109.
    • 18. Amaro MI, Tewes F, Gobbo O, Tajber L, Corrigan OI, Ehrhardt C, Healy AM. 2015. Formulation, stability and pharmacokinetics of sugar­based salmon calcitonin­loaded nanoporous/nanoparticulate microparticles (NPMPs) for inhalation. Int J Pharm 483(1-2):6-18.
    • 19. Belotti S, Rossi A, Colombo P, Bettini R, Rekkas D, Politis S, Colombo G, Balducci AG, Buttini F. 2014. Spray dried amikacin powder for inhalation in cystic fibrosis patients: A quality by design approach for product construction. Int J Pharm 471(1-2):507-515.
    • 20. Razavi Rohani SS, Abnous K, Tafaghodi M. 2014. Preparation and characterization of spray­dried powders intended for pulmonary delivery of insulin with regard to the selection of excipients. Int J Pharm 465(1-2):464-478.
    • 21. Al­fagih I, Alanazi F, Hutcheon G, Saleem I. 2011. Recent Advances Using Supercritical Fluid Techniques for Pulmonary Administration of Macromolecules via Dry Powder Formulations. Drug Delivery Letters 1:128-134.
    • 22. Li X, Vogt FG, Hayes D , Jr., Mansour HM. 2014. Design, characterization, and aerosol dispersion performance modeling of advanced co­spray dried antibiotics with mannitol as respirable microparticles/nanoparticles for targeted pulmonary delivery as dry powder inhalers. J Pharm Sci 103(9):2937-2949.
    • 23. Osman R, Al Jamal KT, Kan PL, Awad G, Mortada N, El­Shamy AE, Alpar O. 2013. Inhalable DNase I microparticles engineered with biologically active excipients. Pulm Pharmacol Ther 26(6):700-709.
    • 24. Jensen DM, Cun D, Maltesen MJ, Frokjaer S, Nielsen HM, Foged C. 2010. Spray drying of siRNA­containing PLGA nanoparticles intended for inhalation. J Control Release 142(1):138-145.
    • 25. Yang SC, Zhu JB. 2002. Preparation and characterization of camptothecin solid lipid nanoparticles. Drug Dev Ind Pharm 28(3):265-274.
    • 26. Lee SH, Heng D, Ng WK, Chan HK, Tan RB. 2011. Nano spray drying: A novel method for preparing protein nanoparticles for protein therapy. Int J Pharm 403(1-2):192-200.
    • 27. Thompson CJ, Hansford D, Higgins S, Hutcheon GA, Rostron C, Munday DL. 2006. Enzymatic synthesis and evaluation of new novel T­pentadecalactone polymers for the production of biodegradable microspheres. J Microencapsul 23(2):213-226.
    • 28. Taguchi G, Yokoyama Y. 1993. Taguchi methods: Design of experiments. ASI Press.
    • 29. Wong W, Crapper J, Chan HK, Traini D, Young PM. 2010. Pharmacopeial methodologies for determining aerodynamic mass distributions of ultra­high dose inhaler medicines. J Pharm Biomed Anal 51(4):853- 857.
    • 30. Myrdal PB, Yalkowsky SH. 2007. Solubilization of drugs in aqueous media. In Encyclopedia of pharmaceutical technology; Swarbrick J , Ed. 3rd ed. New York: Informa Health Care. p 3311.
    • 31. Greenfield NJ. 2006. Using circular dichroism spectra to estimate protein secondary structure. Nat Protoc 1(6):2876-2890.
    • 32. Henzler Wildman KA, Lee DK, Ramamoorthy A. 2003. Mechanism of lipid bilayer disruption by the human antimicrobial peptide, LL­37. Biochemistry 42(21):6545-6558.
    • 33. Whitmore L, Woollett B, Miles AJ, Janes RW, Wallace BA. 2010. The protein circular dichroism data bank, a Web­based site for access to circular dichroism spectroscopic data. Structure 18(10):1267-1269.
    • 34. Whitmore L, Wallace BA. 2004. DICHROWEB, an online server for protein secondary structure analyses from circular dichroism spectroscopic data. Nucleic Acids Res 32(Web Server issue):W668-673.
    • 35. Whitmore L, Wallace BA. 2008. Protein secondary structure analyses from circular dichroism spectroscopy: Methods and reference databases. Biopolymers 89(5):392-400.
    • 36. Abbate V, Kong X, Bansal SS. 2012. Photocrosslinked bovine serum albumin hydrogels with partial retention of esterase activity. Enzyme Microb Technol 50(2):130-136.
    • 37. Zhang J, Ma X, Guo Y, Yang L, Shen Q, Wang H, Ma Z. 2010. Size­controllable preparation of bovine serum albumin­conjugated PbS nanoparticles. Mater Chem Phys 119(1-2):112-117.
    • 38. Bilati U, Allemann E, Doelker E. 2005. Poly(D,L­lactide­coglycolide) protein­loaded nanoparticles prepared by the double emulsion method-processing and formulation issues for enhanced entrapment efficiency. J Microencapsul 22(2):205-214.
    • 39. Bittner B, Kissel T. 1999. Ultrasonic atomization for spray drying: A versatile technique for the preparation of protein loaded biodegradable microspheres. J Microencapsul 16(3):325-341.
    • 40. Yang YY, Chung TS, Ng NP. 2001. Morphology, drug distribution, and in vitro release profiles of biodegradable polymeric microspheres containing protein fabricated by double­emulsion solvent extraction/evaporation method. Biomaterials 22(3):231-241.
    • 41. Cun D, Jensen DK, Maltesen MJ, Bunker M, Whiteside P, Scurr D, Foged C, Nielsen HM. 2011. High loading efficiency and sustained release of siRNA encapsulated in PLGA nanoparticles: Quality by design optimization and characterization. Eur J Pharm Biopharm 77(1):26- 35.
    • 42. Brunner CT, Baran ET, Pinho ED, Reis RL, Neves NM. 2011. Performance of biodegradable microcapsules of poly(butylene succinate), poly(butylene succinate­co­adipate) and poly(butylene terephthalateco­adipate) as drug encapsulation systems. Colloids Surf B Biointerfaces 84(2):498-507.
    • 43. Sanad RA, Abdel Malak NS, El­Bayoomy TS, Badawi AA. 2010. Preparation and characterization of oxybenzone­loaded solid lipid nanoparticles (SLNs) with enhanced safety and sunscreening efficacy: SPF and UVA­PF. Drug Discov Ther 4(6):472-483.
    • 44. Walter E, Moelling K, Pavlovic J, Merkle HP. 1999. Microencapsulation of DNA using poly(DL­lactide­co­glycolide): Stability issues and release characteristics. J Control Release 61(3):361-374.
    • 45. Wischke C, Borchert HH. 2006. Influence of the primary emulsification procedure on the characteristics of small protein­loaded PLGA microparticles for antigen delivery. J Microencapsul 23(4):435-448.
    • 46. Zhang JX, Chen D, Wang SJ, Zhu KJ. 2005. Optimizing double emulsion process to decrease the burst release of protein from biodegradable polymer microspheres. J Microencapsul 22(4):413-422.
    • 47. Li X, Deng X, Yuan M, Xiong C, Huang Z, Zhang Y, Jia W. 1999. Investigation on process parameters involved in preparation of polyDL­lactide­poly(ethylene glycol) microspheres containing Leptospira Interrogans antigens. Int J Pharm 178(2):245-255.
    • 48. Tang ES, Huang M, Lim LY. 2003. Ultrasonication of chitosan and chitosan nanoparticles. Int J Pharm 265(1-2):103-114.
    • 49. Slutter B, Bal S, Keijzer C, Mallants R, Hagenaars N, Que I, Kaijzel E, van Eden W, Augustijns P, Lowik C, Bouwstra J, Broere F, Jiskoot W. 2010. Nasal vaccination with N­trimethyl chitosan and PLGA based nanoparticles: Nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen. Vaccine 28(38):6282-6291.
    • 50. Gutierro I, Hernandez RM, Igartua M, Gascon AR, Pedraz JL. 2002. Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres. Vaccine 21(1- 2):67-77.
    • 51. Shakweh M, Ponchel G, Fattal E. 2004. Particle uptake by Peyer's patches: A pathway for drug and vaccine delivery. Expert Opin Drug Deliv 1(1):141-163.
    • 52. des Rieux A, Fievez V, Garinot M, Schneider YJ, Preat V. 2006. Nanoparticles as potential oral delivery systems of proteins and vaccines: A mechanistic approach. J Control Release 116(1):1-27.
    • 53. Motlekar N. 2009. Optimization of experimental parameters for the production of LMWH­loaded polymeric microspheres. Drug Des Devel Ther 2:39-47.
    • 54. Shi S, Hickey AJ. 2010. PLGA microparticles in respirable sizes enhance an in vitro T cell response to recombinant Mycobacterium tuberculosis antigen TB10.4­Ag85B. Pharm Res 27(2):350-360.
    • 55. Mohajel N, Najafabadi AR, Azadmanesh K, Vatanara A, Moazeni E, Rahimi A, Gilani K. 2012. Optimization of a spray drying process to prepare dry powder microparticles containing plasmid nanocomplex. Int J Pharm 423(2):577-585.
    • 56. Billon A, Bataille B, Cassanas G, Jacob M. 2000. Development of spray­dried acetaminophen microparticles using experimental designs. Int J Pharm 203(1-2):159-168.
    • 57. Baras B, Benoit MA, Gillard J. 2000. Parameters influencing the antigen release from spray­dried poly(DL­lactide) microparticles. Int J Pharm 200(1):133-145.
    • 58. Anish C, Upadhyay AK, Sehgal D, Panda AK. 2014. Influences of process and formulation parameters on powder flow properties and immunogenicity of spray dried polymer particles entrapping recombinant pneumococcal surface protein A. Int J Pharm 466(1-2):198-210.
    • 59. Bhardwaj V, Ankola DD, Gupta SC, Schneider M, Lehr CM, Kumar MN. 2009. PLGA nanoparticles stabilized with cationic surfactant: Safety studies and application in oral delivery of paclitaxel to treat chemical­induced breast cancer in rat. Pharm Res 26(11):2495-2503.
  • No related research data.
  • Discovered through pilot similarity algorithms. Send us your feedback.

Share - Bookmark

Download from

Cite this article